Clinical trials: Depressive Disorder, Major
Older Adults, Anxiety
Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery
Using a Hybrid Type 1 Effectiveness-Implementation randomized control trial (RCT) design, the investigators will test the effectiveness of a bundled behavioral activation and medication optimization in reducing symptoms of…
- Conditions
- Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy
- Trial name
- NCT05685511
- Testing
- Behavioral Activation, Medication Optimization, Usual care resources
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Washington University School of Medicine
Depression, Opioid-use Disorder
Ketamine for the Treatment of Opioid Use Disorder and Depression
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine…
- Conditions
- Depression, Opioid-use Disorder, Opioid Abuse
- Trial name
- NCT04177706
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
Pilot Study of Duloxetine in Psychological Resilience
The purpose of this study is to explore benefits of duloxetine in enhancing psychological resilience and to understand the relevance of inhibiting of both serotonin (5HT) and norepinephrine (NE)to therapeutic responses.
- Trial name
- NCT00331799
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Major Depressive Disorder
iCBT With TMS in Patients With MDD
Major Depressive Disorder (MDD) is a common mental health diagnosis. While there are many approaches to the treatment of MDD, current treatments of MDD often do not substantially reduce depressive symptoms among those in need of…
- Trial name
- NCT05988619
- Testing
- Transcranial Magnetic Stimulation, Internet-Based Cognitive Behavioral Therapy, Psychoeducation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder, Insomnia
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult participants with comorbid major depressive disorder (MDD) and insomnia.
- Trial name
- NCT03771664
- Testing
- SAGE-217
- Where
- 28 sites in United States
- Volunteers
- 87 people
- Sponsor
- Biogen
Major Depressive Disorder
Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Late-life depression is characterized by both affective (mood) symptoms and cognitive deficits. There is currently no intervention that may provide consistent benefits to both mood and cognitive performance.
- Trial name
- NCT02816138
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University Medical Center
Major Depressive Disorder, Dysthymia
Project to Improve Symptoms and Mood in People With Spinal Cord Injury
Depression is likely the most prevalent and disabling psychological complication associated with spinal cord injury (SCI). Yet no controlled depression treatment trials have been performed in this population.
- Conditions
- Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
- Trial name
- PRISMS (NCT00592384)
- Testing
- venlafaxine XR
- Where
- 6 sites in United States
- Volunteers
- 133 people
- Sponsor
- University of Washington
Major Depressive Disorder
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01288079
- Testing
- TC-5214, Duloxetine
- Where
- 63 sites in United States, Estonia and 3 more
- Volunteers
- 145 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Lifestyle Intervention for Young Adults With Serious Mental Illness
This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT02815813
- Testing
- PeerFIT, BEAT
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Depression
Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or…
- Trial name
- NCT00183729
- Testing
- Memantine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Eric Lenze
Depression
Treating Depression With Transcranial Direct Current Stimulation (tDCS)
The purpose of this study is to see if transcranial direct current stimulation may improve the symptoms of depression.
- Trial name
- NCT00481988
- Testing
- transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Mental Disorders, Severe, Schizophrenia and Related Disorders
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
Insufficient community-based support after inpatient discharge for persons with serious mental illnesses (SMI) may lead to re-hospitalization, excessive criminal justice involvement, homelessness, and an inability to embrace…
- Conditions
- Mental Disorders, Severe, Schizophrenia and Related Disorders, Bipolar Disorder, Depressive Disorder
- Trial name
- ODR (NCT04612777)
- Testing
- Opening Doors to Recovery, Case Management, Intensive Case Management
- Volunteers
- 240 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Major Depression
Past Pain Experience and Perception of Experimental Pain
Differences in pain perception between subjects with and without psychiatric illness may be influenced by the individual experience, and not primarily by the pathology, although the pathological frame may amplify it.The aim of…
- Trial name
- NCT01575912
- Testing
- experimental pain tests
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Major Depressive Disorder
Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression
This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD).
- Trial name
- tVNS_MDD_Sex (NCT04448327)
- Testing
- active tVNS
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Improving Therapeutic Learning in Depression: Proof of Concept
Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response and partial-response remain relatively common outcomes, motivating the search for new treatments.
- Trial name
- NCT02376257
- Testing
- 250 mg DCS, 100 mg Modafinil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston University Charles River Campus
Depressive Disorder, Major
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal.
- Trial name
- NCT01389752
- Testing
- LY2216684, Activated Charcoal
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Closed-loop Optimized rTMS for Depression
Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional…
- Trial name
- NCT04142320
- Testing
- Neuronavigated rTMS
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Major Depressive Disorder
A Study in Prevention of Re-emergence of Depression Symptoms
The primary objective of this study was to assess the maintenance of efficacy of LY2216684 compared with placebo as adjunctive therapy to selective serotonin reuptake inhibitors (SSRIs) as measured by the time-to-symptom…
- Trial name
- NCT01299272
- Testing
- LY2216684, SSRI
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 1,249 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor…
- Trial name
- NCT05932407
- Testing
- Vortioxetine Tablet, SSRI
- Where
- Japan
- Volunteers
- 147,777 people
- Sponsor
- Takeda